Clinical Trial Update: Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade NMIBC After BCG Failure [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating safety and efficacy of CG0070 Oncolytic Virus regimen for high-grade non-muscle invasive bladder cancer after BCG failure has …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Drugs mentioned

• CG0070 Oncolytic Virus (CG0070)

Snippet

Sponsor: CG Oncology, Inc. | Conditions: Bladder Cancer | Phase 2 | Status: COMPLETED